Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
crawled time : 22:00 source : Investors.biomarin.com save search
FDA Accepts BioMarin's Supplemental New Drug Application to Expand Use of VOXZOGO® (vosoritide) for Injection to Treat Children with Achondroplasia Under the Age of 5
Published: 2023-03-07 (Crawled : 22:00) - investors.biomarin.com
BMRN | $92.01 2.82% 710K
|
Health Technology
|
| O: 0.12%
H: 1.14%
C: 0.83%
voxzogo fda drug children application achondroplasia injection
BioMarin Announces Record Fourth Quarter and Full Year 2022 Total Revenues Driven by Strong Global Demand for VOXZOGO® and Steady Growth of Enzyme Business
Published: 2023-02-27 (Crawled : 22:00) - investors.biomarin.com
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: -1.4%
H: 0.0%
C: 0.0%
BMRN | $92.01 2.82% 710K
|
Health Technology
|
| O: -3.82%
H: 3.69%
C: 0.29%
voxzogo global year growth
European Medicines Agency Validates Application for Extension of Indication for VOXZOGO® (vosoritide) for injection to Treat Children with Achondroplasia Under the Age of 2
Published: 2023-01-03 (Crawled : 22:00) - investors.biomarin.com
BMRN | $92.01 2.82% 710K
|
Health Technology
|
| O: 3.06%
H: 3.12%
C: 3.12%
voxzogo children extension application injection achondroplasia
BioMarin Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates
Published: 2022-02-23 (Crawled : 22:00) - investors.biomarin.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: 0.0%
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: -4.06%
H: 0.0%
C: 0.0%
BMRN | $92.01 2.82% 710K
|
Health Technology
|
| O: -12.72%
H: 9.46%
C: 7.4%
financial results ces results
BioMarin Provides Updates on Progress in Gene Therapy Programs
Published: 2022-02-17 (Crawled : 22:00) - investors.biomarin.com
BMRN | $92.01 2.82% 710K
|
Health Technology
|
| O: -1.89%
H: 1.47%
C: -4.21%
gene therapy program therapy
BioMarin Demonstrates Enduring Commitment to Advancing the Standard of Care in Hemophilia A at 15th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) February 2-4
Published: 2022-02-02 (Crawled : 22:00) - investors.biomarin.com
BMRN | $92.01 2.82% 710K
|
Health Technology
|
| O: -3.07%
H: 1.15%
C: 0.75%
europe order haemophilia
BioMarin and Skyline Therapeutics Announce Strategic Collaboration to Develop Novel Gene Therapies for Cardiovascular Diseases
Published: 2021-12-16 (Crawled : 22:00) - investors.biomarin.com
BMRN | $92.01 2.82% 710K
|
Health Technology
|
| O: -0.31%
H: 5.57%
C: 3.78%
cardio therapeutics disease gene therapies cardiovascular collaboration gene therapy therapy
BioMarin Appoints Former CEO of Celgene Corporation, Mark Alles, to Board of Directors
Published: 2021-12-15 (Crawled : 22:00) - investors.biomarin.com
TPTX | $76.01 -0.03%
|
Health Technology
|
| O: 1.52%
H: 1.13%
C: -4.27%
SYRS | $5.115 2.51% 60K
|
Health Technology
|
| O: 0.57%
H: 2.84%
C: -4.55%
BMRN | $92.01 2.82% 710K
|
Health Technology
|
| O: 2.83%
H: 0.71%
C: -1.66%
ceo cel
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.64 166.67% 18M
|
AGBA | $2.61 108.8% 41M
|
Finance
CZOO | $9.32 86.77% 18M
|
EDBL | News | $6.7 78.19% 1.7M
|
OPRT | News | $3.37 49.78% 8.9M
|
Finance
MTC | $2.14 37.18% 4.9M
|
Technology Services
VNRX | $0.8 33.33% 2.9M
|
Health Technology
MLEC | $1.79 27.86% 2.6M
|
n/a
PALI | $6.29 27.59% 22M
|
Manufacturing
MCRB | $0.7902 26.51% 6.9M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.